--- title: "Rocatinlimab Halt Puts Spotlight On Amgen Pipeline Risks And Valuation" type: "News" locale: "en" url: "https://longbridge.com/en/news/279853505.md" description: "Amgen and Kyowa Kirin have halted all clinical trials of rocatinlimab due to newly identified safety risks, including malignancy cases. This decision removes a significant immunology asset from Amgen's pipeline. Currently, Amgen's stock trades at $349.92, with a 1-year return of 14.6% and a 5-year return of 66.2%. The discontinuation raises questions about R&D spending and future program replacements. Analysts note the share price is close to the consensus target of $350.55, but recent declines indicate weak momentum. Investors should monitor how this impacts Amgen's research focus and financial health." datetime: "2026-03-19T22:10:37.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279853505.md) - [en](https://longbridge.com/en/news/279853505.md) - [zh-HK](https://longbridge.com/zh-HK/news/279853505.md) --- # Rocatinlimab Halt Puts Spotlight On Amgen Pipeline Risks And Valuation - Amgen and Kyowa Kirin have discontinued all clinical trials of rocatinlimab after newly identified safety risks, including malignancy cases. - The decision removes a high profile immunology asset from Amgen's pipeline and halts further development of the drug. - This move follows internal safety review work and affects ongoing studies across multiple indications. For investors watching NasdaqGS:AMGN, the rocatinlimab decision comes at a time when the stock is trading at $349.92, with a 1 year return of 14.6% and a 3 year return of 64.9%. The 5 year return of 66.2% places recent volatility, including a 4.9% decline over the past week and a 6.3% decline over the past month, in the context of a longer track record of shareholder returns. Rocatimlimab's removal from the pipeline may influence how you think about Amgen's research focus in immunology and inflammation, as well as the risk profile around late stage assets. The key questions now center on how management reallocates R&D spending, which programs step forward to fill this gap, and how safety considerations may shape future portfolio choices for NasdaqGS:AMGN. Stay updated on the most important news stories for Amgen by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Amgen. Is Amgen's balance sheet strong enough for future acquisitions? Dive into our detailed financial health analysis. ### Quick Assessment - **⚖️ Price vs Analyst Target**: At $349.92 versus a consensus target of $350.55, the share price is essentially in line with analyst expectations. - **✅ Simply Wall St Valuation**: Shares are flagged as trading about 46.3% below an estimated fair value, which points to a valuation gap. - **❌ Recent Momentum**: The 30 day return of about 6.3% decline shows weak near term momentum around the rocatinlimab news. There is only one way to know the right time to buy, sell or hold Amgen. Head to Simply Wall St's company report for the latest analysis of Amgen's Fair Value. ### Key Considerations - 📊 Ending rocatinlimab trials removes a late stage immunology asset. Factor in a slightly leaner pipeline when judging future optionality. - 📊 Watch how R&D is reallocated, any commentary on replacement programs, and whether guidance on spending or trial mix changes after this decision. - ⚠️ The existing flag that debt is not well covered by operating cash flow may matter more if pipeline setbacks increase reliance on current cash generators. ### Dig Deeper For the full picture including more risks and rewards, check out the complete Amgen analysis. Alternatively, you can visit the community page for Amgen to see how other investors believe this latest news will impact the company's narrative. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### Related Stocks - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [4151.JP](https://longbridge.com/en/quote/4151.JP.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) ## Related News & Research - [AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH | AMGN Stock News](https://longbridge.com/en/news/286959850.md) - [Amgen Announces CFO Transition and Leadership Succession Plan](https://longbridge.com/en/news/286964358.md) - [Amgen says CFO Peter Griffith to retire, names Dittrich as successor](https://longbridge.com/en/news/286967989.md) - [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md) - [Amgen's rare disease drug linked to deaths, liver injuries in Japan, Kissei reports](https://longbridge.com/en/news/286614551.md)